**Characterization of hepcidin response to holotransferrin in novel recombinant TfR1 HepG2 cells**

### Kosha Mehta1, Mark Busbridge2, Derek Renshaw3, Robert W. Evans4, Sebastien Farnaud5¶ and Vinood B. Patel1¶\*

1Department of Biomedical Sciences, University of Westminster, London, UK

2Department of Clinical Biochemistry, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK

3Faculty of Health & Life Sciences, Coventry University, Coventry, UK

4School of Engineering and Design, Brunel University, London, UK

5Department of Life Sciences, University of Bedfordshire, Luton, UK

¶Equal contribution

\*Corresponding author: Dr Vinood Patel, Department of Biomedical Sciences, University of Westminster, London W1W 6UW, UK, [Tel.:0207 911 5000](Tel:02079115000) ext. 64138; Fax: 0207 911 5087; Email: [v.b.patel@westminster.ac.uk](mailto:v.b.patel@westminster.ac.uk)

**Abstract**

Hepcidin is the key regulator of systemic iron homeostasis. The iron-sensing mechanisms and the role of intracellular iron in modulating hepatic hepcidin secretion are unclear. Therefore, we created a novel cell line, recombinant-TfR1 HepG2, expressing iron-response-element-independent *TFRC* mRNA to promote cellular iron-overload and examined the effect of excess holotransferrin (5 g/L) on cell-surface TfR1, iron content, hepcidin secretion and mRNA expressions of *TFRC*, *HAMP*, *SLC40A1*, *HFE* and *TFR2*. Results showed that the recombinant cells exceeded levels of cell-surface TfR1 in wild-type cells under basal (2.8-fold; p<0.03) and holotransferrin-supplemented conditions for 24 h and 48 h (4.4- and 7.5-fold, respectively; p<0.01). Also, these cells showed higher intracellular iron content than wild-type cells under basal (3-fold; p<0.03) and holotransferrin-supplemented conditions (6.6-fold at 4 h; p<0.01). However, hepcidin secretion was not higher than wild-type cells. Moreover, holotransferrin treatment to recombinant cells did not elevate *HAMP* responses compared to untreated or wild-type cells. In conclusion, increased intracellular iron content in recombinant cells did not increase hepcidin responses compared to wild-type cells, resembling hemochromatosis. Furthermore, *TFR2* expression altered within 4 h of treatment, while *HFE* expression altered later at 24 h and 48 h, suggesting that TFR2 may function prior to HFE in *HAMP* regulation.

**Keywords:** hepcidin, iron, HepG2, hepatocyte, transferrin

**Introduction**

Hepcidin, the 25-mer iron-hormone is secreted by the liver hepatocytes in response to increased systemic iron levels in the body (1,2). It binds to ferroportin, the iron-exporter protein on hepatocytes, duodenal enterocytes and splenic and liver macrophages (3–5) and causes intracellular degradation of both hepcidin and ferroportin (6). Hepcidin thus prevents iron efflux via ferroportin into the circulation and acts as the main regulator of systemic iron homeostasis. Accordingly, insufficient systemic hepcidin levels lead to elevated duodenal iron absorption and uncontrolled iron efflux into the circulation. This causes progressive iron accumulation in vital organs such as liver, pancreas and heart, eventually resulting in organ failure due to iron toxicity. These features are hallmarks of the iron-overload heredity hemochromatosis (7,8) and also observed in alcoholic liver disease (9,10).

The extracellular and intracellular iron-sensing mechanisms of hepatocytes that lead to hepcidin synthesis and secretion in response to circulatory iron are not clearly defined yet. In this context, previous studies suggested roles of plasma transferrin (Tf) and stored intracellular iron in the induction of *HAMP*, gene encoding hepcidin (11–13). In addition, intracellular iron was proposed to induce the maturation of pro-hepcidin into secretable bioactive hepcidin (14). However, its precise role in hepcidin peptide secretion has not been sufficiently studied. Alongside, although the proteins HFE and TFR2 on the hepatocytes are pivotal in *HAMP* induction (15), their mechanisms of action, whether independent or in conjunction, remain ambiguous (16–18). Collectively, the complete picture of hepcidin regulation and secretion in response to iron is yet to be fully elucidated.

Hence, here, the effect of excess holo-Tf and the consequently altered intracellular iron content on hepcidin secretion (at peptide level) and synthesis (at mRNA level) was examined simultaneously. Since hepcidin is secreted predominantly by the hepatocytes, the liver–derived cell line, HepG2, was chosen for the study. Cellular iron-uptake is mediated by the cell-surface protein TfR1, which is regulated at the iron-response element (IRE) region on its mRNA via the IRE/iron-regulatory protein (IRP) system (19). Here, using wild-type (Wt) HepG2 cells, a novel recombinant HepG2 cell line was created that expressed IRE-independent *TFRC* mRNA to diminish sensitivity towards increasing intracellular iron content and allow intracellular iron overload. It was hypothesized that upon holo-Tf treatment, these recombinant (rec)-TfR1 HepG2 cells would demonstrate higher intracellular iron content and consequently, alter hepcidin peptide secretion and *HAMP* mRNA responses compared to Wt cells. Previous *ex vivo* studies investigated *HAMP* regulation only at longer time-points such as 24 hours (h), 48 h and 72 h (20–24). Here, we studied the effects of holo-Tf on hepcidin secretion for short-term i.e. at 30 minutes (min), 2 h and 4 h, in addition to long-term i.e. 24 h and 48 h, in conjunction with mRNA expression studies of key iron-related genes such as *TFRC*, *HAMP*, *SCL40A1*, *HFE*, and *TFR2*.

**Materials and methods**

**Cell culture**

HepG2 cells (Health Protection Agency, UK) were maintained in Eagle’s Minimum Essential Medium (EMEM) (Sigma-Aldrich UK), 1 % non-essential amino acids (NEAA) (Sigma-Aldrich UK), 2 mM glutamax (Fisher Scientific International Inc. UK), 1 % antibiotic/antimycotic solution (Fisher Scientific International Inc. UK) and 10 % fetal calf serum (FCS) (Biosera, UK). Rec-TfR1 HepG2 cells expressing IRE-independent human *TFRC* mRNA were created (supplementary data-1) and maintained in 200 µg/mL hygromycin B (Invitrogen, UK) as a selection for exclusive growth of recombinant cells. *TFRC-IRE* mRNA response was explored by probing the mRNA (cDNA) of rec-TfR1 HepG2 cells and Wt HepG2 cells (as control) with the *IRE*-specific primers (GGTTGCTAAGAAGCGAGCAC and TGCTCCCGATAATGTGTTAGG). As an additional reference, the cDNA was probed with *TFRC*- specific primers (supplementary figures 1A -1B). Results showed diminished *TFRC-IRE*-specific amplification in the rec-TfR1 HepG2 cells (Fig.1A), indicating diminished *IRE*-related responsiveness, as desired for the study. Also, a HepG2 cell line with the unmodified plasmid vector [HepG2 (p) cells] was created for pre-iron-supplementation studies (supplementary data-2 and supplementary figures (2A-2C).

**Holo-Tf supplementation**

The iron saturation of holo-Tf and the iron content of the treatment medium

were assessed (supplementary data-3 and supplementary figures 3A-3B). Cells were seeded at a density of 5 X 105 per well in a 6-well plate in maintenance medium (with and without hygromycin B for rec-TfR1 HepG2 cells and Wt cells, respectively) for 72 h. For the next 24 h, all cells were incubated in fresh hygromycin-free maintenance medium. Then, the cells were treated with 5 g/L holo-Tf prepared in serum-free EMEM (0 g/L) for the desired period and assessed for various parameters.

**Determination of intracellular iron content and assessment of mitochondrial activity**

Cellular iron content determined by the ferrozine assay (25) was expressed as nmoles of iron per mg of protein, as quantified by the Bradford method. Mitochondrial activity was assessed by using the MTT assay (26). To compare the mitochondrial activity of cells in between different treatments, 2.5 X 104 cells were seeded per well of a 96 well plate in maintenance medium. The plate was incubated overnight at 37 ºC in a humidified atmosphere with 5 % CO2. The following day, the maintenance medium was removed and the cells were washed twice with warm PBS to remove traces of the maintenance medium. Treatment media were then added to each well and the plates were again incubated at 37 ºC in a humidified atmosphere with 5 % CO2. On completion of the treatment exposure period, the old media were replaced with 200 µL of fresh media per well. This was followed by addition of 5 µL per well of 5 mg/mL of MTT prepared in PBS. The plates were incubated at 37 °C for 2 h, the media were removed and 100 µL DMSO was added to each well. Plates were incubated at RT for 15 min, vortexed for 30 sec and absorbance was read at 550 nm using a spectrophotometer. The absorbance values of blanks (medium only) were subtracted from controls and treated samples. This assay was appropriate for our study because it measures the mitochondrial activity (26) and the mitochondrion is a major organelle for ROS production (27), especially under excess iron conditions (28,29). Thus, mitochondrial activity was chosen as a marker of cell/mitochondrial health over other markers.

**Cell-surface TfR1 expression**

Cells were harvested using TrypLE Express (ThermoFisher Scientific, UK), followed by centrifugation for 4 min at 89 x *g*. Cells were suspended in PBC (PBS containing 0.15 % BSA and 1 mM calcium chloride) and transferred to a 96-well plate (2 X 105 cells per well) and centrifuged at 1,260 x *g* for 30 sec. To each well, 20 µL of 16 mg/mL blocking IgG was added. Human TfR1 antibody (Abcam, UK) [5 µg/mL in PBC)] was added to each test well and PBC was added to the control wells. Cells were incubated for 45 min on ice. Following washing, the cells were incubated with 10 µg/mL of FITC-labeled secondary antibody STAR9B rabbit F (ab') 2 anti-mouse IgG (ABD Serotec, UK). After incubation for 30 min on ice, cells were washed with PBC again. Cell layer at the bottom of each well was suspended in 400 µL of PBS and TfR1 expression was analyzed by flow cytometry (30). For the gating of cells for flow cytometry, first, live cells were selected based on the forward and side scatter. On the selected cell population, the positive threshold was determined based on the staining results obtained in the absence of the TfR1 antibody (cells treated with secondary antibody only). This selected a cell population of TfR1 positive cells. Then, the position of the gate was kept fixed while assessing samples from Wt and rec-TfR1 HepG2 cells and samples from different treatment conditions for both the cell lines. This enabled relative comparisons between the cell types and in between treatments.

**Gene expression analysis**

Primers (Invitrogen, UK) for expression analyses of the genes *TFRC* (NCBI accession no.[NM\_001128148.1](http://www.ncbi.nlm.nih.gov/nucleotide/189458818?report=genbank&log$=nucltop&blast_rank=14&RID=M2KZDSA1016)), *HAMP* (NCBI accession no.AF309489.1) and *GAPDH* (NCBI accession no. NM\_002046.4) were designed [*Primer 3* ([*http://frodo.wi.mit.edu/)*](http://frodo.wi.mit.edu/))] (supplementary data-4). RNA was extracted using TRI reagent (Sigma-Aldrich, UK) and converted to cDNA using QuantiTect reverse transcription kit (Qiagen, UK), as per manufacturer’s protocol. Gene expression was analyzed through real-time PCR by using Quantifast SYBR green kit (Qiagen, UK) according to the manufacturer’s protocol. Real-time PCRs were carried out in the Rotor-gene Q machine (Qiagen, UK) and the results were analyzed through Rotor-gene software series 1.7.Data was analyzed by the relative quantification method, Delta-Delta Ct (∆∆Ct) and expressed as 2 -∆∆Ct (31).

**Hepcidin peptide levels**

The concentration of hepcidin peptide secreted in the cell media was measured by using a previously well-described immunoassay by Busbridge et al. (32).

**Statistical analysis**

Data analysis was performed using one-way or two-way ANOVA, with post-hoc analysis by Tukey’s test using the software SPSS, version 22. The level of significance was set at p<0.05. Data was presented as mean ± SEM.

**Results**

**Characterization of novel rec-TfR1-HepG2 cells in basal conditions**

The rec-TfR1 HepG2 cells showed significantly higher *TFRC* mRNA expression (2.2-fold; p<0.03) and iron content than Wt cells (3-fold; p<0.03) (Fig.1A and 1B). However, hepcidin secretion levels were similar to the Wt cells (Fig.1C). These cells expressed substantially higher levels of *SLC40A1* (8.8-fold; p<0.05), but did not significantly differ from the Wt HepG2 cells in mRNA expressions of *HAMP, HFE* and *TFR2* (Fig.1D), whilst mitochondrial activity increased by 30 % (p<0.05) (Fig.1E). Under basal conditions, the rec-TfR1 HepG2 cells displayed significantly higher cell-surface TfR1 levels than Wt cells (2.8-fold; p<0.03) (Fig.2).

**Rec-TfR1-HepG2 cells under holo-Tf-supplemented conditions**

**Cell-surface TfR1 and *TFRC* mRNA expression:** Following holo-Tf treatment, the Wt cells displayed a significant decrease in cell-surface TfR1 over time at 24 h (p<0.04), which further declined at 48 h (p<0.01) (Fig.2 and supplementary Fig.4). Conversely, the rec-TfR1 HepG2 cells maintained high levels following 24 h and 48 h of holo-Tf treatment and showed significantly higher levels than Wt cells at these times (p<0.01) (Fig.2 and supplementary Fig.4). The rec-TfR1 HepG2 cells showed no statistically significant difference in TfR1 levels under holo-Tf-treated and basal conditions (Fig.2). In addition, *TFRC* mRNA expression was assessed and compared to respective untreated (0 g/L) cells at each corresponding time-point. The Wt cells showed significantly decreased *TFRC* mRNA expression at 2 h (p<0.05), 4 h (p<0.05) and 24 h (p<0.05) (Fig.3). In contrast, rec-TfR1 HepG2 cells showed significant 3-fold elevations in *TFRC* mRNA expression at 2 h (p<0.05) and 24 h (p<0.02) (Fig.3). In the Wt HepG2 cells, decreased *TFRC* mRNA expression following holo-Tf treatment for 24 h and 48 h (Fig.3) correlated with decreased cell-surface TfR1 levels observed at these time-points (Fig.2). However, in rec-TfR1 HepG2 cells, the correlation was less clear.

**Intracellular iron levels:** Upon holo-Tf treatment, the rec-TfR1 HepG2 cells showed higher intracellular iron content than Wt cells at 30 min (3.3-fold, p<0.03), 2 h (3.7-fold, p<0.01), 4 h (6.6-fold, p<0.01), 24 h (5.7-fold, p<0.01) and 48 h (2.2-fold, p<0.01) (Fig.4). Even under holo-Tf deprivation (0 g/L), the rec-TfR1 HepG2 cells showed higher intracellular iron content than Wt cells at 30 min (3.6-fold, p<0.01), 2 h (3.2-fold, p<0.01), 4 h (2.8-fold, p<0.01), 24 h (2.5-fold, p<0.01) and 48 h (1.9-fold, p<0.03) (Fig.4).

Over time, the Wt cells showed no major variation in intracellular iron content upon holo-Tf deprivation and treatment (Fig.4). In contrast, during short-term treatment, the rec-TfR1 HepG2 cells showed a pattern of increasing iron-uptake compared to respective untreated (0 g/L) cells at the same time-point i.e. no significant uptake at 30 min, a 1.4-fold increase at 2 h (p<0.02) and a 3.1-fold increase at 4 h (p<0.01) (Fig.4). Also, a 2.4-fold increase (p<0.01) in iron-uptake was observed at 24 h of holo-Tf treatment (Fig.4).

**Hepcidin peptide levels:** Despite the substantially higher intracellular iron content in rec-TfR1 HepG2 cells (Fig.4), hepcidin secretion in these cells was not higher than Wt cells (Fig.5A and Fig.5B). However, both, Wt and rec-TfR1 HepG2 cells secreted significantly higher levels of hepcidin upon holo-Tf supplementation in comparison to their respective untreated (0 g/L) cells (Fig.5). For example, the Wt HepG2 cells

showed significantly elevated hepcidin secretion at 2 h (p<0.02), 4 h (p<0.02), 24 h (p<0.02) and 48 h (p<0.02) (Fig.5A). Likewise, the rec-TfR1 HepG2 cells showed elevated hepcidin secretion at 30 min (p<0.05), 2 h (p<0.02), 4 h (p<0.02), 24 h (p<0.02) and 48 h (p<0.02) (Fig.5B).

Upon holo-Tf deprivation (0 g/L), hepcidin peptide secretion gradually decreased over time in both, Wt and rec-TfR1 HepG2 cells (Fig.5); from 2 h to 24 h (1.6-fold; p<0.05), and further decreased at 48 h (2.2-fold; p<0.02) in Wt cells (Fig.5A) and from 30 min to 24 h (3.1-fold; p<0.04),and further decreased at 48 h (3.4-fold; p<0.03) in recombinant cells (Fig. 5B).

**Gene expression analyses:** The mRNA expression of core iron-related genes were assessed and compared to respective untreated (0 g/L) cells at each corresponding time-point. In Wt cells, *HAMP* mRNA expression significantly increased at 4 h (2.2 fold; p<0.05) and 24 h (1.6 fold; p<0.02), whereas in rec-TfR1 HepG2 cells, it significantly increased only at 2 h (1.5-fold; p<0.02) (Fig.6A). While *SLC40A1* mRNA expression remained unaltered in Wt cells (Fig.6B), in rec-TfR1 HepG2 cells, an unaltered response at 30 min, a 1.8-fold increase at 2 h (p<0.05) and a 3-fold increase at 4 h (p<0.05) was observed, followed by unchanged expression at 24 h and 48 h of holo-Tf treatment (Fig.6B).

Both, Wt and rec-TfR1 HepG2 cells showed no change in *HFE* mRNA expression during short-term treatment (Fig.7A). However, it was down-regulated at 48 h (2.7-fold, p<0.05) in Wt cells and at 24 h (2.7-fold, p<0.05) in rec-TfR1 HepG2 cells (Fig.7A). In contrast, *TFR2* mRNA expression remained unaltered at 24h and 48 h and altered earlier during short-term treatment in both, Wt and rec-TfR1 HepG2 cells (Fig.7B). However, the two cell types exhibited different *TFR2* mRNA responses to treatment. In Wt cells, *TFR2* mRNA expression was up-regulated at 30 min (2.3-fold, p<0.05), and later again at 4 h (2.9-fold, p<0.05), whereas in rec-TfR1 HepG2 cells, *TFR2* mRNA expression was significantly reduced at 4 h (p<0.01), compared to untreated (0 g/L) cells (Fig.7B). Following 5 g/L treatment, there was no major alteration in mitochondrial activity except the 40 % increase in Wt cells at 48 h (p<0.05), compared to untreated (0 g/L) cells at the same time-point (Fig.8).

**Discussion**

The liver-secreted iron-hormone hepcidin is the master regulator of systemic iron homeostasis in the body. However, the iron-sensing mechanisms in the hepatocytes are not fully understood. A role of intracellular iron in modulating hepcidin secretion (14) and *HAMP* mRNA expression (11–13) was suggested, but not fully elucidated. Accordingly, here, for the first time, novel rec-TfR1 HepG2 cells were created that expressed IRE-independent *TFRC* mRNA to diminish sensitivity towards high intracellular iron and to allow continuous iron-uptake upon holo-Tf supplementation. In these cells, the combined effect of excess extracellular holo-Tf and the subsequently increased intracellular iron on hepcidin secretion was examined over time for the first time, in conjunction with mRNA expression studies of key iron-related genes like *TFRC*, *HAMP*, *SLC40A1*, *HFE* and *TFR2*. The responses of this novel cell line were compared with those of the Wt cells.

**Deregulated cell-surface TfR1 and high iron content in recombinant cells**

Upon holo-Tf treatment, the Wt cells down-regulated cell-surface TfR1 levels over time (Fig.2). This was an anticipated response because the IRE-replete *TFRC* transcripts would sense increments in intracellular iron content via the IRE/IRP system and eventually decrease TfR1 protein expression on cell-surface to prevent further iron-uptake (33). Accordingly, and as expected, the Wt cells showed no major variation in intracellular iron content following holo-Tf treatment (Fig.4), resembling physiological conditions and other studies where 4.5 g/L of holo-Tf treatment for 48 h did not significantly increase iron content (34).

In contract, the rec-TfR1 HepG2 cells displayed several fold higher cell-surface TfR1 than Wt cells under basal and prolonged holo-Tf-supplemented conditions (Fig.2), despite their several fold higher intracellular iron content than Wt cells (Fig.1B and Fig.4). Such an unexpected response could be because the recombinant *TFRC* construct in rec-TfR1 HepG2 cells was devoid of the IRE region and therefore independent from the IRE-mediated iron-regulatory mechanisms (35). This iron-insensitive feature was also reflected through up-regulated *TFRC* mRNA expression following holo-Tf treatment, unlike the Wt cells that showed down-regulated expression (Fig.3). In Wt cells, the reduced *TFRC* mRNA expression at 24 h (Fig.3) is consistent with the previously observed decrease following 2.5 g/L of holo-Tf treatment for 24 h (24). Thus, contrasting the Wt cells, rec-TfR1 HepG2 cells demonstrated constitutively elevated cell-surface TfR1regardless of excess extracellular holo-Tf and high intracellular iron content, as required for this study.

Both, Wt and rec-TfR1 HepG2 cells exceeded basal levels of hepcidin secretion upon holo-Tf treatment and decreased hepcidin levels over time upon holo-Tf deprivation (0 g/L) (Fig.5 and Fig.1C). This is similar to the human response where increased circulatory iron levels lead to increased circulatory hepcidin levels (1,36–38) and reduced hepcidin response prevails under iron deficiency (37,39). Interestingly, upon holo-Tf treatment, the Wt cells exceeded the basal level by 1.7-fold at 4 h and markedly reduced hepcidin secretion at 24 h (Figs.1C and 5). A similar pattern has been reported in humans where an oral dose of 65 mg of iron led to a 2-fold increase in hepcidin levels after 4 h and returned to baseline levels after 24 h (38).

The intracellular iron status of the cells is not only related to iron-uptake via TfR1 but also related to cellular iron efflux mediated by regulations in the iron-efflux gene *SLC40A1*. Here, *SLC40A1* expression remained unaltered in Wt HepG2 cells at all time points (Fig.6B). In the rec-TfR1 HepG2 cells, it was upregulated at the early contiguous time points (2 h and 4 h), but remained unaltered at the longer contiguous time points (24 h and 48 h). This difference in the responses between short-term and long-term treatments could be due to the presence of 5’ IREs on the *SLC40A1* mRNA. These sense intracellular iron-increments in the rec-TfR1 HepG2 cells at a particular treatment time-point and resultantly increase expression to promote cellular iron-efflux (19).Thus, its expression would be determined by the intracellular iron status at a particular treatment time-point and therefore vary.

**Hepcidin levels and intracellular iron content**

The rec-TfR1 HepG2 cells demonstrated higher iron content than Wt cells under basal and holo-Tf-supplemented conditions (Fig.1B and Fig.4). However, hepcidin secretion in the rec-TfR1 HepG2 cells did not exceed the levels secreted by the Wt cells, in neither basal nor holo-Tf-supplemented conditions (Fig.1C and Fig.5).

Thus, here, hepcidin secretion did not alter in proportion to the increased intracellular iron levels in the rec-TfR1 HepG2 cells, compared to Wt cells. This suggests that possibly, the proposed post-translation maturation of pro-hepcidin to bioactive hepcidin (14) may well be mediated by intracellular iron levels, requiring only subtle amounts of iron-uptake to trigger the maturation of pro-hepcidin to secretable hepcidin. This was reflected in Wt cells, which, following holo-Tf treatment, exceeded basal hepcidin secretion levels (Fig.1C and Fig.5) without any major iron-uptake (Fig.4).

***HAMP* mRNA response to holo-Tf treatment in recombinant cells**

Following holo-Tf supplementation, although intracellular iron levels in rec-TfR1 HepG2 cells were substantially higher than Wt cells (Fig.4), *HAMP* mRNA responses did not proportionately exceed the responses of Wt cells (Fig.6A). In fact, the rec-TfR1 HepG2 cells showed an elevated response only at 2 h while the Wt cells showed elevated expression at 4 h and 24 h (Fig.7A). This could be due to several reasons. Firstly, excess cell-surface TfR1on rec-TfR1 HepG2 cells would have changed the native ratios of TfR1 with its hepcidin-inducing binding partners on the cell-surface, HFE and TFR2 (40,41). This may have caused the majority of the HFE to bind to TfR1, aiming to regulate iron-uptake (40,42), thereby limiting the availability of free HFE for *HAMP* induction (43), with or without TFR2 (16,17). Secondly, the down-regulated expression of *TFR2* following holo-Tf treatment (Fig.7B) may have prevented *HAMP* up-regulation in rec-TfR1 HepG2 cells (Fig.6A). In contrast, the Wt cells showed significantly elevated *TFR2* mRNA responses at 30 min and 4 h (Fig.7B) that matched the pattern of *HAMP* mRNA expression in these cells (Fig.6A). This reemphasizes and supports the role of TFR2 in modulating *HAMP* induction following holo-Tf stimulus (20,44).

Unlike Tf, which is known to influence hepcidin expression (45), the relationship between TfR1 (membrane-bound or soluble) and hepcidin expression remains unclear. In this study, the presence of high levels of membrane-bound TfR1 on rec-TfR1 HepG2 cells did not correlate with *HAMP* mRNA expression or secretion (Fig.2, Fig.6A and Fig.5B).The high holo-Tf concentration (5 g/L) utilized provided the conditions for holo-Tf –TfR1 binding to occur, as demonstrated by the excess cellular iron-uptake by the rec-TfR1 HepG2 cells (Fig.4). Following holo-Tf treatment, these cells demonstrated up to 6.6-fold higher intracellular iron content than the Wt HepG2 cells and showed increased iron-uptake over a 4 h period (Fig.4). This suggests that any soluble TfR1 in the medium had not significantly affected the binding of holo-Tf with TfR1, else we would not expect to see increased iron uptake as observed in this study over the 4 h time period (Fig.4). The binding of holo-Tf with TfR1 would also lead to potential *HAMP* induction via the holo-Tf-TfR1 pathway. This reduced the probability that the diminished *HAMP* induction could be due to limited availability of holo-Tf, resulting from the probable binding of soluble TfR1 to holo-Tf in the medium. Furthermore, increased circulating soluble TfR1 generally occurs in Iron Deficiency Anemia reviewed in (46,47)**.**

The BMP/SMAD, MAPK, IL6-JAK/STAT3, Matripase-2/HJV and hypoxia pathways are important in regulating *HAMP* mRNA expression (7,8) and investigation into these pathways would certainly lead to improved insights into hepcidin signaling. However, these pathways would highlight the transcriptional regulation of hepcidin and not hepcidin peptide secretion. The latter was the focus of this study, which was based on the previously proposed role of intracellular iron in the maturation of pro-hepcidin to release the bioactive 25-mer hepcidin (14). Accordingly, it was hypothesized that increased intracellular iron levels would cause more maturation of pro-hepcidin to secrete more hepcidin. Thus, the effect of excess intracellular iron (as in these iron-overloaded recombinant cells) on hepcidin peptide secretion was evaluated, which has not been sufficiently studied so far, rather than *HAMP* mRNA regulation, which has been extensively studied. Moreover, each of these signal transduction pathways is dynamic, involves several proteins and therefore each pathway accounts for an independent study on its own. This was beyond the scope of the present study, which prioritized hepcidin peptide secretion over regulation of *HAMP* transcription.

***TFR2* and *HFE* mRNA expression in recombinant cells**

In both, Wt and rec-TfR1 HepG2 cells, *HFE* mRNA responses to holo-Tf treatment remained unchanged during short-term treatment and altered later at 24 h and 48 h (Fig.7A).The down-regulation in *HFE* mRNA expression at 24 h in the Wt cells is similar to that observed previously upon 4.5 g/L holo-Tf treatment (34). Unlike the *HFE* mRNA responses, *TFR2* mRNA responses significantly altered during short-term treatment and remained unaltered at 24 h and 48 h in both the cell lines (Fig.7B). In the Wt cells, this was also observed in earlier studies where *TFR2* mRNA expression remained unchanged after 24 h of 4 g/L holo-Tf treatment (20). Together, the data suggests that TFR2 may act prior to HFE in iron and hepcidin regulation, as also proposed earlier (20,38).

**Virtual hemochromatosis**

The rec-TfR1 HepG2 cells displayed several “hemochromatotic” characteristics such as hepcidin secretion disproportionate to iron-overload (Fig.5 and Fig.4), insufficient *HAMP* mRNA response upon holo-Tf stimulus (Fig.6A) (48), up-regulated *SLC40A1* mRNA expression (Fig.6B) (38,49) and putative digression from the normal physiological ratio between TfR1 and HFE on the cell-surface (Fig.2). Thus, these cells may be described as “virtually hemochromatotic” as the cells displayed several “hemochromatotic” characteristics despite possessing the Wt alleles of the hepcidin-inducing genes (16,17,20), mutations in which cause hemochromatosis (7).

**Conclusion**

The novel rec-TfR1 HepG2 cells showed constitutively over-expressed cell-surface TfR1 and higher intracellular iron content than Wt cells under basal and holo-Tf supplemented conditions. However, under the conditions studied this did not lead to higher hepcidin secretion levels compared to Wt cells, suggesting other regulatory mechanisms are involved.

**Acknowledgements:** Thanks to Dr Pamela Greenwell (University of Westminster) for advice on real-time PCR.

**Financial support:** Dr Kosha Mehta was supported by a scholarship from the University of Westminster.

**Conflict of interest:** Kosha Mehta, Mark Busbridge, Derek Renshaw, Robert W. Evans, Sebastien Farnaud and Vinood B. Patel declare that they have no conflict of interest.

**Compliance with Ethical Requirements:** This article does not contain any studies conducted on human or animal subjects.

**Author contributions**

Dr Kosha Mehta: Key researcher; carried out experimental work and wrote the article

Dr Mark Busbridge: Measurement of hepcidin peptides

Derek Renshaw: Provided protocol for analysis of TfR1 by flow cytometry and provided cell culture facility.

Prof. Robert W. Evans: Helped with the assessment of iron-saturation of holo-Tf

Dr Sebastien Farnaud: Concept of the research.

Dr Vinood B. Patel: Director of studies and final approver for the version of the article to be published

**Abbreviations:** EMEM, Eagle’s minimal essential medium; h, hours; IRE, iron

responsive element; IRP, iron regulatory protein; min, minutes; MTT, 3-(4,5-

Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PAGE, polyacrylamide gel

electrophoresis; sec seconds; Tf, transferrin; TfR, transferrin receptor.

**Gene annotations**: *HAMP*, encoding the peptide hepcidin; *HFE* (High iron), gene encoding the hepcidin-inducing hemochromatosis protein HFE; *SLC40A1*, gene encoding the cellular iron-exporter protein ferroportin; *TFR2*, gene encoding the hepcidin-inducing protein transferrin receptor 2 (TFR2); *TFRC*, gene encoding the cellular iron-uptake protein transferrin receptor 1 (TfR1).

# References

1. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001 Mar 16;276(11):7811–9.

2. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001 Mar 16;276(11):7806–10.

3. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000 Jun 30;275(26):19906–12.

4. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000 Feb 17;403(6771):776–81.

5. Ramey G, Deschemin J-C, Durel B, Canonne-Hergaux F, Nicolas G, Vaulont S. Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica. 2010 Mar;95(3):501–4.

6. Preza GC, Pinon R, Ganz T, Nemeth E. Cellular catabolism of the iron-regulatory peptide hormone hepcidin. PloS One. 2013;8(3):e58934.

7. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010 Aug;139(2):393–408, 408-2.

8. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011 Apr 28;117(17):4425–33.

9. Costa-Matos L, Batista P, Monteiro N, Simões M, Egas C, Pereira J, et al. Liver hepcidin mRNA expression is inappropriately low in alcoholic patients compared with healthy controls. Eur J Gastroenterol Hepatol. 2012 Oct;24(10):1158–65.

10. Ohtake T, Saito H, Hosoki Y, Inoue M, Miyoshi S, Suzuki Y, et al. Hepcidin is down-regulated in alcohol loading. Alcohol Clin Exp Res. 2007 Jan;31(1 Suppl):S2-8.

11. Ramos E, Kautz L, Rodriguez R, Hansen M, Gabayan V, Ginzburg Y, et al. Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatol Baltim Md. 2011 Apr;53(4):1333–41.

12. Díaz V, Gammella E, Recalcati S, Santambrogio P, Naldi AM, Vogel J, et al. Liver iron modulates hepcidin expression during chronically elevated erythropoiesis in mice. Hepatol Baltim Md. 2013 Dec;58(6):2122–32.

13. Zhao N, Nizzi CP, Anderson SA, Wang J, Ueno A, Tsukamoto H, et al. Low intracellular iron increases the stability of matriptase-2. J Biol Chem. 2015 Feb 13;290(7):4432–46.

14. Farnaud S, Rapisarda C, Bui T, Drake A, Cammack R, Evans RW. Identification of an iron-hepcidin complex. Biochem J. 2008 Aug 1;413(3):553–7.

15. Pietrangelo A. Molecular insights into the pathogenesis of hereditary haemochromatosis. Gut. 2006 Apr;55(4):564–8.

16. D’Alessio F, Hentze MW, Muckenthaler MU. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. J Hepatol. 2012 Nov;57(5):1052–60.

17. Schmidt PJ, Fleming MD. Transgenic HFE-dependent induction of hepcidin in mice does not require transferrin receptor-2. Am J Hematol. 2012 Jun;87(6):588–95.

18. Rishi G, Crampton EM, Wallace DF, Subramaniam VN. In situ proximity ligation assays indicate that hemochromatosis proteins Hfe and transferrin receptor 2 (Tfr2) do not interact. PloS One. 2013;8(10):e77267.

19. Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr. 2008;28:197–213.

20. Rapisarda C, Puppi J, Hughes RD, Dhawan A, Farnaud S, Evans RW, et al. Transferrin receptor 2 is crucial for iron sensing in human hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2010 Sep;299(3):G778-783.

21. Dzikaite V, Holmström P, Stål P, Eckes K, Hagen K, Eggertsen G, et al. Regulatory effects of tumor necrosis factor-alpha and interleukin-6 on HAMP expression in iron loaded rat hepatocytes. J Hepatol. 2006 Mar;44(3):544–51.

22. Fein E, Merle U, Ehehalt R, Herrmann T, Kulaksiz H. Regulation of hepcidin in HepG2 and RINm5F cells. Peptides. 2007 May;28(5):951–7.

23. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003 Apr 1;101(7):2461–3.

24. Gehrke SG, Kulaksiz H, Herrmann T, Riedel H-D, Bents K, Veltkamp C, et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood. 2003 Jul 1;102(1):371–6.

25. Riemer J, Hoepken HH, Czerwinska H, Robinson SR, Dringen R. Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem. 2004 Aug 15;331(2):370–5.

26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1–2):55–63.

27. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009 Jan 1;417(Pt 1):1–13.

28. Gao X, Campian JL, Qian M, Sun X-F, Eaton JW. Mitochondrial DNA Damage in Iron Overload. J Biol Chem. 2009 Feb 20;284(8):4767–75.

29. Lee HJ, Choi JS, Lee HJ, Kim W-H, Park SI, Song J. Effect of excess iron on oxidative stress and gluconeogenesis through hepcidin during mitochondrial dysfunction. J Nutr Biochem. 2015 Dec;26(12):1414–23.

30. Rosignoli G, Lim CH, Bower M, Gotch F, Imami N. Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Clin Exp Immunol. 2009 Jul;157(1):90–7.

31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif. 2001 Dec;25(4):402–8.

32. Busbridge M, Griffiths C, Ashby D, Gale D, Jayantha A, Sanwaiya A, et al. Development of a novel immunoassay for the iron regulatory peptide hepcidin. Br J Biomed Sci. 2009;66(3):150–7.

33. Casey JL, Hentze MW, Koeller DM, Caughman SW, Rouault TA, Klausner RD, et al. Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. Science. 1988 May 13;240(4854):924–8.

34. Jacolot S, Férec C, Mura C. Iron responses in hepatic, intestinal and macrophage/monocyte cell lines under different culture conditions. Blood Cells Mol Dis. 2008 Aug;41(1):100–8.

35. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci. 2004 Mar;1012:1–13.

36. Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V, Ganz T. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood. 2007 Sep 15;110(6):2182–9.

37. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008 Nov 15;112(10):4292–7.

38. Girelli D, Trombini P, Busti F, Campostrini N, Sandri M, Pelucchi S, et al. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica. 2011 Apr;96(4):500–6.

39. Choi HS, Song SH, Lee JH, Kim H-J, Yang HR. Serum hepcidin levels and iron parameters in children with iron deficiency. Korean J Hematol. 2012 Dec;47(4):286–92.

40. Feder JN, Penny DM, Irrinki A, Lee VK, Lebrón JA, Watson N, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1472–7.

41. Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem. 2006 Sep 29;281(39):28494–8.

42. Waheed A, Grubb JH, Zhou XY, Tomatsu S, Fleming RE, Costaldi ME, et al. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3117–22.

43. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab. 2008 Mar;7(3):205–14.

44. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood. 2005 Feb 15;105(4):1803–6.

45. Bartnikas TB, Andrews NC, Fleming MD. Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice. Blood. 2011 Jan 13;117(2):630–7.

46. Li H, Ginzburg YZ. Crosstalk between Iron Metabolism and Erythropoiesis. Adv Hematol [Internet]. 2010 [cited 2016 Jun 9];2010. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902017/

47. Berlin T, Meyer A, Rotman-Pikielny P, Natur A, Levy Y. Soluble transferrin receptor as a diagnostic laboratory test for detection of iron deficiency anemia in acute illness of hospitalized patients. Isr Med Assoc J IMAJ. 2011 Feb;13(2):96–8.

48. Vujić M. Molecular basis of HFE-hemochromatosis. Front Pharmacol. 2014;5:42.

49. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DHG, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet Lond Engl. 2003 Feb 22;361(9358):669–73.

**Figure captions**

Fig.1 Basal iron-related cellular parameters in rec-TfR1 HepG2 cells

Fig.2 Cell-surface expression of TfR1 following holo-Tf treatment

Fig.3 mRNA expression of *TFRC* following holo-Tf treatment

Fig.4 Intracellular iron levels following holo-Tf treatment

Fig. 5 Hepcidin secretion following holo-Tf treatment

Fig.6 mRNA expression of *HAMP* and *SLC40A1* following holo-Tf treatment

Fig.7 mRNA expression of *HFE* and *TFR2* following holo-Tf treatment

Fig.8 Mitochondrial activity following holo-Tf treatment

# Figure Legends

**Fig 1. Rec-TfR1 HepG2 cells in basal conditions (10%FCS).**

(A) *TFRC* mRNA expression, (B) Intracellular iron content, (C) hepcidin peptide secretion, (D) mRNA expression of iron-related genes in rec-TfR1 HepG2 cells in comparison with Wt HepG2 cells and (E) relative mitochondrial activity and are shown. Data is presented as mean ± SEM (n=3). \*p<0.05 and \*\*p<0.03 compared to Wt HepG2 cells.

**Fig2. Effect of holo-Tf treatment on TfR1 cell-surface expression.**

HepG2 cells were treated with 5 g/L holo-Tf up to 48 h and total cell-surface expression of TfR1 before treatment (basal conditions) and after treatment was studied by flow cytometry. (A-C) Representative images for each treatment for Wt HepG2 cellsand (D-F) rec-TfR1 HepG2 cells have been shown and the effect of treatment has been summarized in (G). Data is presented as mean ± SEM (n=3-6). \*p<0.03 and\*\*p<0.01 compared to Wt HepG2 cellsat the corresponding time-point; #p<0.04 compared to Wt HepG2 cellsin basal conditions; ##p<0.01 compared to Wt HepG2 cellsfollowing treatment at 24 h.

**Fig 3. Effect of holo-Tf treatment on *TFRC* mRNA expression.**

Upon 5 g/L holo-Tf treatment, mRNA expression of *TFRC* was assessed and expressed relative to respective untreated (0 g/L) cells at the corresponding time-point. Data is presented as mean ± SEM (n=3). \*p<0.05, \*\*p<0.02 compared to untreated (0 g/L) cells at the corresponding time-point.

**Fig 4. Effect of holo-Tf treatment on iron-uptake.**

Intracellular iron levels were measured following holo-Tf deprivation and treatment. Data is presented as mean ± SEM (n=3-6). \*p<0.03, \*\*p<0.01 compared to Wt HepG2 cells at the corresponding time-point and #p<0.02,##p<0.01 compared to untreated (0 g/L) rec-TfR1 cells at the corresponding time-point.

**Fig 5. Effect of holo-Tf treatment on hepcidin peptide secretion.**

Levels of secreted hepcidin were measured following holo-Tf treatment and deprivation in wt HepG2 cells (A) and rec-TfR1HepG2 cells (B). Data is presented as mean ± SEM (n=3-6). \*p<0.05, \*\*p<0.02 compared to respective untreated (0 g/L) cells at the corresponding time-point; #p<0.05,##p<0.02 compared to 2 h of 0 g/L treatment in Wt HepG2 cells; ^p<0.04, ^^p<0.03 compared to 30 min of 0 g/L treatment in rec-TfR1 HepG2 cells.

**Fig 6. Effect of holo-Tf treatment on *HAMP* and *SLC40A1* mRNA expression.**

Upon 5 g/L holo-Tf treatment, mRNA expression of (A) *HAMP* and (B)*SLC40A1*in the HepG2 cells was assessed and expressed relative to respective untreated (0 g/L) cells at the corresponding time-point. Data is presented as mean ± SEM (n=3). \*p<0.05, \*\*p<0.02 compared to untreated (0 g/L) cells at the corresponding time-point.

**Fig 7. Effect of holo-Tf treatment on *HFE and TFR2* mRNA expression.**

Upon 5 g/L holo-Tf treatment, mRNA expression of (A)*HFE* and(B)*TFR2* in the HepG2 cells was assessed and expressed relative to respective untreated (0g/L) cells at the corresponding time-point. Data is presented as mean ± SEM (n=3). \*p<0.05 compared to untreated (0 g/L) cells at the corresponding time-point.

**Fig 8. Effect of holo-Tf treatment on mitochondrial activity.**

Following 5 g/L holo-Tf treatment, mitochondrial activity of HepG2 cells was assessed and expressed in comparison to untreated (0 g/L) cells at the corresponding time-point. Data is presented as mean ± SEM (n=3-6). \*p<0.05 compared to Wt HepG2 cells.

**Characterization of hepcidin response to holotransferrin in novel recombinant TfR1 HepG2 cells**

**Revised Figures**

**Fig. 1**

**A B C**

**\*\***

**\*\***

**D E**

**\***

**\***

**Fig. 2**

**\***

**#**

**##**

**\*\***

**\*\***

**Fig. 3**

**\*\***

**\***

**\***

**\***

**\***

**Fig. 4**

**\*\***

**#**

**\*\***

**\***

**\*\***

**\*\***

**\*\***

**\*\***

**\*\***

**\***

**\*\***

**##**

**##**

**Fig. 5A**

**##**

**#**

**\*\***

**\*\***

**\*\***

**\*\***

**Fig. 5B**

**\*\***

**\***

**\*\***

**^^**

**^**

**\*\***

**\*\***

**Fig. 6A**

**\*\***

**\***

**\***

**Fig. 6B**

**\***

**\***

**Fig. 7A**

**\***

**\***

**Fig. 7B**

**\***

**\*\***

**\***

**Fig. 8**

**\***

**Characterization of hepcidin response to holotransferrin in novel recombinant TfR1 HepG2 cells**

**Revised supplementary information**

**Supplementary data-1: Creation of recombinant–TfR1 HepG2 cells**

Principally, the protein coding region of human *TFRC* devoid of its *IRE* region was cloned into the plasmid vector pCEP4 (Invitrogen-Life technologies, UK) and transfected into Wt HepG2 cells, resultantly giving rise to the rec-TfR1 HepG2 cells. Briefly, the primers (Invitrogen-Life technologies, UK) TfR1F (TGATATATGCGGCCGCACCATGGATCAAGCTAGATCAGCATTCTC) incorporating a NotI site and a Kozak sequence and TfR1R (GCGCGCGGATCCTTATTAAAACTCATTGTC AATGTCCCAAACGTC) incorporating a BamHI site were used for PCR amplification of the specific section of full length *TFRC* gene from human MGC verified cDNA (clone ID 3354176, Invitrogen-Life technologies, UK). PCR was carried out with KOD DNA hot start polymerase mix (Novagen, UK) as follows: Initial denaturation at 95 ºC for 3 min, then 30 cycles of denaturation at 95 ºC for 30 sec, annealing at 58 ºC for 1 min and extension at 72 ºC for 1 min, followed by a final extension at 72 ºC for 5 min. The PCR product was gel extracted and purified by using PCR product purification kit (Qiagen, UK), then cut with HF-NotI/HF-BamH1 (New England Biolabs, UK) and ligated into HF-NotI/BamHI cut and phosphatased pCEP4. The ligation mixture was used to transform *Escherichia coli* KRX cells (Promega Ltd, UK) and colonies were selected on Luria-Bertani medium containing 100 µg/mL ampicillin (Sigma-Aldrich UK). Recombinant plasmid from one colony was sequenced to confirm the presence of the *TFRC* gene. HepG2 cells were transfected with recombinant pCEP4 by using X-tremeGENE-9 DNA transfection reagent (Roche,UK) as per manufacturer’s protocol.

**Supplementary Fig. 1**

**A B**

\*

\*

\*

\*

\*

\*

\*\*

**Supplementary Fig 1. *TFRC-IRE* responses in rec-TfR1 HepG2 cells**

Following holo-Tf treatments, the rec-TfR1 HepG2 (A) and Wt HepG2 cells (B) were probed with *TFRC*-specific and *IRE-*specific (TFRC-IRE) primers and the expressions were measured, as explained in the methods. Data is presented as mean ± SEM (n=3). \*p <=0.05 and \*\*p <0.01 compared to untreated cells (0 g/L) at the same time-point.

**Supplementary data-2-Pre-iron supplementation studies**

A HepG2 cell line with the unmodified plasmid vector was created for reference and referred to as HepG2 (p) cells. Study of the main iron-related parameters in the HepG2 (p) cells showed no difference from the Wt HepG2 cells (supplementary Fig.2). For example, similarities with the Wt HepG2 cells were observed in cell-surface TfR1 levels under basal conditions (supplementary Fig.2A) and following iron-supplementation over time (supplementary Fig.2B). Moreover, following holo-Tf treatment, hepcidin peptide levels in the HepG2 (p) cells matched levels in the Wt HepG2 cells (supplementary Fig.2C). In addition, intracellular iron levels in the HepG2 (p) cells were similar to Wt HepG2 cells under basal conditions over time (4.7 to 6 nmoles/ mg protein) and upon holo-Tf treatment (6.5 nmoles/ mg protein). The relative mitochondrial activity was either 90-95 % similar or showed no difference from the Wt HepG2 cells (data not shown for brevity). Thus, further parameters in HepG2 (p) cells were not studied and subsequent studies were conducted using Wt HepG2 cells as reference to enable comparison with other groups that have also used Wt HepG2 cells for iron supplementation studies.

**Supplementary Fig. 2**

**A B**

\*

#

**C**

**Supplementary Fig 2. Cell-surface TfR1 and hepcidin expression in HepG2 (p) cells.**

(A) Cell-surface TfR1 expression in HepG2 (p) cells in comparison to Wt HepG2 cells under basal conditions and (B) following 5 g/L holo-Tf treatment are shown. (C) Hepcidin peptide secreted by Wt HepG2 and HepG2 (p) cells under basal conditions and following holo-Tf treatment were measured. Data is presented as mean ± SEM (n=3). \*p <0.03 compared to basal conditions and #p=0.05 compared to 24 h of 5 g/L treatment in HepG2 (p) cells.

**Supplementary data-3- Assessment of iron saturation and iron content in treatment medium**

Holo-Tf was prepared by iron–loading apo-Tf using 0.1 M stock solution of ferric citrate, at a final molar concentration equal to twice the transferrin molar concentration. The iron-saturation in 5 g/L holo-Tf was assessed by PAGE on 6 M urea gel, as per Evans et al., (1978). Data suggested that 90 % of the protein was diferric (supplementary Fig. 2A). Iron content in 5 g/L holo-Tf medium was determined by the ferrozine assay, as per Reimer et al., (2004), which was 93 % of the expected iron molarity in the holo-Tf preparation (supplementary Fig.2B).


**Supplementary Fig. 3**

**A B**

**N-monoferric transferrin**

**C-monoferric transferrin**

**Holotransferrin**



**1 2**

**Supplementary Fig. 3. Determination of iron saturation and iron concentration of treatment medium.**

(A) Iron content in iron-loaded transferrin was determined by 6 M urea PAGE. Lane 1: apo-transferrin; lane 2: 5 g/L holotransferrin. The three species of iron-transferrin, C-and N-monoferric transferrin and holotransferrin can be observed with a major proportion of holotransferrin. (B) Measurement of iron concentration in treatment medium confirmed iron concentration of expected morality. 0 g/L corresponds to serum-free and holo-Tf-free maintenance medium, whereas 5 g/L corresponds to serum-free maintenance medium supplemented with 5 g/L holo-Tf. Data is presented as mean ± SEM (n=3).

**Supplementary data-4- Primers**

The primers used for RTPCR were AAAATCCGGTGTAGGCACAG (F) and TTAAATGCAGGGACGAAAGG (R) for *TFRC* (Mehta et al., 2015), ACAGCCAGACAGACGGCACGA (F) and TTCGCCTCTGGAACATGGGCATC (R) for *HAMP*, GCCAAAAGGGTCATCATCTC (F) and GGTGCTAAGCAGTTGGTGGT (R) for *GAPDH*, TGTTTCTGGTAGAGCTCTAT (F) and GATATAGCAGGAAGTGAGAA (R) for *SLC40A1* (Jacolot et al., 2008)*,* TGATCTGGGAGCCCTCACC (F) and GACGACAAAAACAGCAATTCC (R) for *HFE* (Jacolot et al., 2008), TATACTCCTGGAGCTGGTGC (F) and GCACGCTGAGGTAGCCCTCTA (R) for *TFR2* (Rapisarda et al., 2010). Prior to expression analysis, PCRs using cDNA templates were performed by using Taq PCR master mix (Qiagen, UK) as per manufacturer’s instruction. The amplicons were sequenced at Wolfson Institute for Biomedical Research (University College London, UK) to confirm product identity.

**Supplementary Fig. 4**



**A**

****

**B**

**Basal 24 h (5 g/L) 48 (5 g/L)**

**Supplementary Fig 4. Cell-surface TfR1 in rec-TfR1 HepG2 cells**

Cell-surface TfR1 expression were assessed by flow cytometry, as explained in the methods. Representative images of Wt HepG2 cells (panel A) and rec-TfR1 HepG2 cells (panel B) following different treatments are shown.